Cardiff Oncology (CRDF) CEO Mani Mohindru Buys $30K of Stock

Mani Mohindru, the Chief Executive Officer of CRDF, recently bought 24,703 shares of the company at $1.21 each. This transaction, which took place on June 18, 2026, had a total value of approximately $29,890.63. The purchase was not part of a pre-arranged trading plan.

Other Institutional Activity in CRDF

Several institutional investors have also been active in CRDF recently. BlackRock, Inc. trimmed its holdings by 62,227 shares, ending with 3,981,387 shares worth about $6,449,847. Vanguard Capital Management LLC opened a new position with 2,855,966 shares valued at approximately $4,626,665. Meanwhile, Laurion Capital Management LP held steady with 2,646,738 shares valued around $4,287,716. Acorn Capital Advisors, LLC reduced its stake by 200,000 shares, leaving it with 1,762,084 shares worth $2,854,576. Geode Capital Management, LLC increased its holdings by 76,648 shares to a total of 1,599,663 shares, valued at $2,592,106.

Cardiff Oncology, Inc. Stock Down 5.1%

Shares of CRDF traded near $1.21 on Monday. The company has seen substantial movement in its stock due to recent insider and institutional activities. While specific financial metrics like market cap and P/E ratio were not provided, the stock's current price and recent trading volumes suggest active investor interest.

Insider Buying and Selling at Cardiff Oncology, Inc.

In addition to Mohindru's purchase, other insiders were also buying shares. Gary Pace acquired 30,000 shares on June 18 at $1.22 each. On June 11, several insiders, including Renee Tannenbaum and Rodney Markin, each bought 40,565 shares at unspecified prices. These transactions were not part of any pre-arranged trading plans.

Analysts Set New Price Targets

Analyst opinions on CRDF are varied. On June 3, 2026, Craig-Hallum downgraded the stock to a 'hold' with a $2.00 price target. Piper Sandler maintained a 'buy' rating with a target of $6.00 back in February 2026. HC Wainwright & Co. reiterated its 'buy' rating with a $10.00 target in January 2026. These differing views reflect the mixed sentiment in the market regarding CRDF's future prospects.

Bottom Line

Mani Mohindru's recent purchase of CRDF shares underscores her confidence in the company. Institutional investors are also actively adjusting their positions, indicating varying levels of interest and strategy. Analyst ratings remain mixed, with some firms maintaining optimistic targets while others take a more cautious stance. As always, it's important for investors to consider these insights as part of the larger picture when evaluating CRDF's potential.